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Patients with relapsed HD may be cured with high-dose chemotherapy followed by ASCT. [2] [3] In an attempt to induce greater tumor eradication, more intense regimens have been tried with variable success and toxicity. 4 Sometimes the choice of one preparative regimen over the other is based on patient characteristics and status of disease at the time of transplantation. A high-dose regimen containing BU, melphalan and thiotepa (BuMelTT) was initially used in hematological malignancies by the Fred Hutchinson Cancer Center in Seattle, Washington. 5, 6 One study was conducted to compare the efficacy and toxicity profiles of BuMelTT vs more standard BEAM in patients with non-Hodgkin's lymphoma. 7 In that report, both regimens were similar in efficacy in patients with lymphoma, but BuMelTT seemed to be relatively more toxic. In another report from Seattle, BuMelTT was compared with radiation-based preparative regimens in patients with relapsed/refractory HD. 8 No differences in toxicities and efficacy between the conditioning regimens were found. The authors concluded that patients with prior irradiation benefited from BuMelTT regimen. We retrospectively evaluated our center's experience of different preparative regimens in patients with relapsed/refractory HD undergoing ASCT. Granulocyte colony-stimulating factor-mobilized PBSCs were used for ASCT in all patients. BuMelTT regimen 8 Table 1 Preparative regimen, status at transplantation and outcome for patients with Hodgkin's disease undergoing ASCT In all, 9 patients received BuMelTT and 14 patients received BEAM or BEAC (BCNU, etoposide, Ara-C, and melphalan or CY) as standard preparative regimens before ASCT. To keep the groups closely matched, we excluded all patients who were transplanted as outpatients. In the latter part of 2009, our center changed the standard preparative regimen from BEAM to BEAC; hence the last three patients in the standard arm received BEAC instead of BEAM. Preparative regimens, status at transplantation and outcomes for patients with HD undergoing ASCT are shown in Table 1 .
The probability of disease-free survival and OS were 55 and 83% in BuMelTT group and 43 and 85% in the BEAM/ BEAC group at 1 year with a median duration of follow-up of 17 months. In this study, the disease-free survival and OS in the BuMelTT group (43 and 83% at 1 year) were comparable with the published literature. 10 The OS in patients transplanted with active disease were similar between the two groups (BuMelTT 83% vs BEAM/BEAC 85%) at 1 year. More patients in the BuMelTT group (100%) developed mucositis compared with patients in the BEAM/BEAC group (50%). There was no difference in the engraftment kinetics between the two groups. Average length of stay was longer in BuMelTT (median 21 days; range 18-22) compared with BEAM/BEAC group (median 18 days; range 9-36; P ¼ 0.016) with more observed inpatient cost with BuMelTT (mean: $51 650; range $33 242-166 867 vs $40 730; range $22, 661-63 668; P ¼ 0.03). This could have been secondary to more mucositis noted in patients receiving BuMelTT. To our knowledge, this is the first report of LOS and cost analysis of two high-dose preparative regimens in the management of relapsed/refractory HD.
Our study had several limitations. It was a retrospective study with a small number of patients and relatively short follow-up (median duration of follow-up 17 months). Allocation to the two treatment groups was by physician discretion with the possibility of introduction of bias. There was an imbalance favoring patients with active disease toward BuMelTT arm and favoring older patients toward BEAM/ BEAC. More patients with active disease were treated with BuMelTT (8 out of 9; 89%) than BEAM/BEAC (10 out of 14; 72%). To answer the question whether BuMelTT had any advantage over standard BEAM/BEAC in patients with relapsed/refractory HD, a prospective randomized study using a larger number of patients should be conducted.
We conclude that BuMelTT as a preparative regimen was feasible in patients with relapsed/refractory HD, but was associated with more mucositis, longer transplantrelated hospital length of stay and greater observed cost.
